Clinical Trials Browser

Active not recruiting × Neoplasm Metastasis × Gastrointestinal × Clear all

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT04514484 2026-03-18

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Phase 1 Active not recruiting

750 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07457541 2026-03-12

Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI

Phase 1 Active not recruiting

15 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04449874 2026-02-12

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1 Active not recruiting

498 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT05863052 2026-02-10

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Active not recruiting

72 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Gastrointestinal Neoplasms, Melanoma, Neoplasm Metastasis

Clinical Trials

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

MASST

SOLSTICE

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

SHIELD-1

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

RAMP205

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

AFPᶜ³³²T in Advanced HCC

Hepatic Resection for Metastatic Pancreatic Cancer

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

A Study to Assess an ATX Inhibitor (IOA-289) in Patients with Metastatic Pancreatic Cancer

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

INGA

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Edwards EVOQUE Eos MISCEND Study

9-ING-41 in Patients with Advanced Cancers

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

TRANSMET

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer